# EDGAR Filing Document

**Accession Number:** 0001479915
**File Stem:** 0001493152-26-023151
**Filing Date:** 2026-5
**Character Count:** 76682
**Document Hash:** 97075d7f7775852a1ab5d874acc3ddbd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-023151.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001493152-26-023151

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 42

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CQENS Technologies Inc.
- **CENTRAL INDEX KEY:** 0001479915
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 271521364
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55470
- **FILM NUMBER:** 26980006

**BUSINESS ADDRESS:**
- **STREET 1:** 5550 NICOLLET AVENUE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55419
- **BUSINESS PHONE:** 612-812-2037

**MAIL ADDRESS:**
- **STREET 1:** 5550 NICOLLET AVENUE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55419

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VapAria Corp
- **DATE OF NAME CHANGE:** 20140820

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OICco ACQUISITION IV, INC.
- **DATE OF NAME CHANGE:** 20100105

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

![](form10-q_001.jpg)

**FORM 10-Q**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the quarterly period ended March 31, 2026

or

☐ **TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from ___________ to _____________

Commission file number 000-55470

**CQENS Technologies Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **27-1521407** |
| (State or other jurisdiction<br> of incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **170 South Green Valley Parkway, Suite 343, Henderson NV** | **89012** |
| (Address of principal executive offices) | (Zip code) |

---

**(702) 661-2404** 

(Registrant's telephone number, including area code)

**not applicable**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| None | not applicable | not applicable |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. 27,582,752 shares of common stock are issued and outstanding as of May 13, 2026.

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | Page No. |
|  | **[PART 1 - FINANCIAL INFORMATION](#a_001)** |  |
| Item 1. | [Financial Statements (Unaudited).](#a_002) | 2 |
| Item 2. | [Management Discussion and Analysis of Financial Condition and Results of Operations.](#a_003) | 11 |
| Item 3. | [Quantitative and Qualitative Disclosures About Market Risk.](#a_004) | 15 |
| Item 4. | [Controls and Procedures.](#a_005) | 15 |
|  | **[PART II - OTHER INFORMATION](#a_006)** |  |
| Item 1. | [Legal Proceedings.](#a_007) | 16 |
| Item 1A. | [Risk Factors.](#a_008) | 16 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds.](#a_009) | 16 |
| Item 3. | [Defaults upon Senior Securities.](#a_010) | 16 |
| Item 4. | [Mine Safety Disclosures.](#a_011) | 17 |
| Item 5. | [Other Information.](#a_012) | 17 |
| Item 6. | [Exhibits.](#a_013) | 17 |

---

i

**CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION**

This report includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "aim," "will," "would," "could," and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future events and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial needs. Forward-looking statements include, but are not limited to, statements about:

● our history of losses, lack of revenues and insufficient working capital;

● our ability to continue as a going concern; and

● our ability to raise capital.

● our limited operating history and lack of products;

● the joint venture with Firebird Manufacturing, LLC remains inactive;

● potential conflicts of interest of our management;

● reliance on joint venture partners and third parties;

● potential U.S. Food and Drug Administration (the "FDA") oversight;

● lack of marketing and distribution experience;

● possible inability to establish and maintain strategic partnerships; and

● possible dependence on licensing or collaboration agreements.

● lack of public market for our common stock; and

● possible impact of Delaware's anti-takeover statutes on our stockholders.

You should read thoroughly this report and the documents that we refer to herein with the understanding that our actual future results may be materially different from and/or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements, Part 1. Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended December 31, 2025 as filed on April 15, 2026 (the "2025 10-K") and our other filings with the Securities and Exchange Commission. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. These forward-looking statements speak only as of the date of this report, and you should not rely on these statements without also considering the risks and uncertainties associated with these statements and our business.

**OTHER PERTINENT INFORMATION**

Unless specifically set forth to the contrary, when used in this report the terms "CQENS," "we," "our," "us," and similar terms refer to CQENS Technologies Inc., a Delaware corporation. In addition, "first quarter of 2026 refers to the three months ended March 31, 2026, "first quarter of 2025" refers to the three months ended March 31, 2025, "2026" refers to the year ended December 31, 2026, and "2025" refers to the year ended December 31, 2025. The information which appears on our web site at <u>www.cqens.com</u> is not part of this report.

**PART 1 - FINANCIAL INFORMATION**

**Item 1. Consolidated Financial Statements**

**CQENS Technologies, Inc.**

**Consolidated Balance Sheets**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | March 31,<br> 2026 | December 31,<br> 2025 |
| ASSETS |  |  |
| &nbsp;&nbsp;&nbsp;Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $8149093 | $8914107 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 316228 | 360360 |
| &nbsp;&nbsp;&nbsp;Total Current Assets | 8465321 | 9274467 |
| &nbsp;&nbsp;&nbsp;Intellectual property, net | 1809302 | 1741808 |
| &nbsp;&nbsp;&nbsp;Furniture and equipment, net | 34542 | 37161 |
| &nbsp;&nbsp;&nbsp;Other intangible assets, net | 11916 |  |
| &nbsp;&nbsp;&nbsp;Right-of-use asset - lease, net | 164790 | 193185 |
| &nbsp;&nbsp;&nbsp;Construction in progress | 2321489 | 2321489 |
| TOTAL ASSETS | $12807360 | $13568110 |
| LIABILITIES & STOCKHOLDERS' EQUITY |  |  |
| LIABILITIES |  |  |
| &nbsp;&nbsp;&nbsp;Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $235961 | $219300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 336537 | 249374 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related party loan | 1486427 | 1256364 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of lease liability | 125940 | 121765 |
| &nbsp;&nbsp;&nbsp;Total Current Liabilities | 2184865 | 1846803 |
| &nbsp;&nbsp;&nbsp;Lease liability, net of current portion | 38850 | 71420 |
| TOTAL LIABILITIES | 2223715 | 1918223 |
| STOCKHOLDERS' EQUITY |  |  |
| &nbsp;&nbsp;&nbsp;Preferred Stock: $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025. |  |  |
| &nbsp;&nbsp;&nbsp;Common Stock: $0.0001 par value; 200,000,000 shares authorized; 27,579,752 shares issued and outstanding at March 31, 2026 and 27,573,752 shares issued and outstanding at December 31, 2025 | 2759 | 2758 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 59285689 | 58965838 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (10653) | (4845) |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (49163580) | (47789247) |
| TOTAL CQENS TECHNOLOGIES STOCKHOLDER'S EQUITY | 10114215 | 11174504 |
| &nbsp;&nbsp;&nbsp;Non-controlling interests | 469430 | 475383 |
| TOTAL STOCKHOLDERS' EQUITY | 10583645 | 11649887 |
| TOTAL LIABILITIES & STOCKHOLDERS' EQUITY | $12807360 | $13568110 |

---

See accompanying notes to unaudited consolidated financial statements

**CQENS Technologies, Inc.**

**Consolidated Statements of Operations and Comprehensive Loss**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | Three months ended March 31, | Three months ended March 31, |
|  | 2026 | 2025 |
| Operating Expenses |  |  |
| &nbsp;&nbsp;&nbsp;General and administrative | $447208 | $337992 |
| &nbsp;&nbsp;&nbsp;Research and development | 450910 | 318743 |
| &nbsp;&nbsp;&nbsp;Professional fees | 526427 | 1915383 |
| Total Operating Expenses | 1424545 | 2572118 |
| Total Operating Loss | (1424545) | (2572118) |
| Other Income | 47724 | 78341 |
| Net Loss | (1376821) | (2493777) |
| &nbsp;&nbsp;&nbsp;Net loss attributable to non-controlling interests | (2488) | (14625) |
| Net Loss attributable to CQENS Technologies, Inc. | $(1374333) | $(2479152) |
| Basic and diluted loss per common share | $(0.05) | $(0.09) |
| Basic and diluted weighted average shares outstanding | 27575952 | 27060695 |
| Comprehensive Loss: |  |  |
| &nbsp;&nbsp;&nbsp;Change in foreign currency translation adjustments | (9273) | 42 |
| Comprehensive Loss: | (1386094) | (2493735) |
| &nbsp;&nbsp;&nbsp;Comprehensive loss attributable to non-controlling interests | (5953) | (14604) |
| Comprehensive loss attributable to CQENS Technologies, Inc. | $(1380141) | $(2479131) |

---

See accompanying notes to unaudited consolidated financial statements

**CQENS Technologies, Inc**

**Consolidated Statements of Changes in Stockholders' Equity**

**For the three months ended March 31, 2026 and 2025**

**(Unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Common Stock | Common Stock | | | | | | |
|  | Number of<br>Shares | $0.0001 Par<br>Value |<br>Additional<br> Paid in<br>Capital |<br>Accumulated<br>Deficit | Accumulated<br>Other<br> Comprehensive<br>Loss |<br>Total |<br>Non-controlling<br>Interest |<br>Total |
| Balance, December 31, 2025 | 27573752 | $2758 | $58965838 | $(47789247) | $(4845) | $11174504 | $475383 | $11649887 |
| &nbsp;&nbsp;&nbsp;Common stock issued for cash | 6000 | 1 | 119999 |  |  | 120000 |  | $120000 |
| &nbsp;&nbsp;&nbsp;Stock options expense |  |  | 199852 |  |  | 199852 |  | $199852 |
| &nbsp;&nbsp;&nbsp;Other comprehensive loss |  |  |  |  | (5808) | (5808) | (3465) | $(9273) |
| &nbsp;&nbsp;&nbsp;Net consolidated loss | - | - | - | (1374333) | - | (1374333) | (2488) | $(1376821) |
| Balance, March 31, 2026 | 27579752 | $2759 | $59285689 | $(49163580) | $(10653) | $10114215 | $469430 | $10583645 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Common Stock | Common Stock | | | | | | |
|  | Number of<br>Shares | $0.0001 Par<br>Value |<br>Additional<br> Paid in<br>Capital |<br>Accumulated<br>Deficit | Accumulated<br>Other<br> Comprehensive<br>Loss |<br>Total |<br>Non-controlling<br>Interest |<br>Total |
| Balance, December 31, 2024 | 26828383 | $2683 | $39068448 | $(34763794) | $(40) | $4307297 | $(4747) | $4302550 |
| &nbsp;&nbsp;&nbsp;Common stock issued for cash | 503750 | 50 | 10074950 |  |  | 10075000 |  | $10075000 |
| &nbsp;&nbsp;&nbsp;Common stock issued for services | 45169 | 5 | 903375 |  |  | 903380 |  | $903380 |
| &nbsp;&nbsp;&nbsp;Stock options expense |  |  | 460020 |  |  | 460020 |  | $460020 |
| &nbsp;&nbsp;&nbsp;Other comprehensive loss |  |  |  |  | 21 | 21 | 21 | $42 |
| &nbsp;&nbsp;&nbsp;Net consolidated loss | - | - | - | (2479152) | - | (2479152) | (14625) | $(2493777) |
| Balance, March 31, 2025 | 27377302 | $2738 | $50506793 | $(37242946) | $(19) | $13266566 | $(19351) | $13247215 |

---

See accompanying notes to unaudited consolidated financial statements

**CQENS Technologies Inc.**

**Consolidated Statements of Cash Flows**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | Three months ended March 31, | Three months ended March 31, |
|  | 2026 | 2025 |
| **Cash flows from operating activities** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(1376821) | $(2493777) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expense | 46530 | 36741 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease expense | 28395 | 16449 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation expense | 3161 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock options expense | 199852 | 460020 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for services |  | 903380 |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 44132 | 9090 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 16661 | 15537 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease liability | (28395) | (16449) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 87163 | (48363) |
| **Net cash used in operating activities** | (979322) | (1117372) |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Additions to intellectual property | (113718) | (147508) |
| &nbsp;&nbsp;&nbsp;Additions to other intangible assets | (12244) |  |
| &nbsp;&nbsp;&nbsp;Additions to property, plant and equipment | - | (869584) |
| **Net cash used in investing activities** | (125962) | (1017092) |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock | 120000 | 9225000 |
| &nbsp;&nbsp;&nbsp;Investor deposits | - | 100000 |
| &nbsp;&nbsp;&nbsp;Borrowing from related parties | 230063 | 60612 |
| **Net cash provided by financing activities** | 350063 | 9385612 |
| &nbsp;&nbsp;&nbsp;Effect of exchange rate changes on cash | (9793) | 42 |
| &nbsp;&nbsp;&nbsp;Net change in cash and cash equivalents | (765014) | 7251190 |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents, beginning of period | 8914107 | 4596556 |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents, end of period | $8149093 | $11847746 |

---

See accompanying unaudited consolidated financial statements

**CQENS Technologies, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

**NOTE 1 - NATURE OF BUSINESS AND SUMMARY OF BASIS OF PRESENTATION** 

Nature of Business

CQENS Technologies, Inc. ("we", "our", the "Company", "CQENS") is a technology company with a proprietary method of heating consumable formulations that produce an aerosol that lead to the effective and efficient inhalation of the active ingredients. This is accomplished at a high temperature but without the accompanying constituents of combustion. Our system of heating is a high temperature, non-combustion system. Our Heated Tobacco Product (HTP) system is a patented method of heating consumables for inhalation that we believe is superior to other methods of ingestion, smoking, vaping, or via topical application.

On December 20, 2023, we entered into a Shareholder Agreement with Asahi Corporation Limited ("Asahi") to establish CQENS Electronics (Hong Kong) Limited ("CEL"), a Hong Kong company, for design, development and manufacture of our heat-not-burn device ("Device"). CQENS acquired 50% membership of CEL and holds majority of board seats including the chair. Pursuant to the establishment of CEL, CQENS entered into an exclusive, worldwide License Agreement with CEL for designing and manufacturing a consumer device consistent with our intellectual property. CEL activities are included in our unaudited consolidated financial statements.

In January 2026, we established a wholly owned foreign entity, Shenzhen CQENS Technology Co. Ltd. ("Shenzhen CQENS"), in China for research and development activities in concert with our US-based research and development team to moving prototypes through the design for manufacturability process and working closely with CEL. In the first quarter of 2026, we made an investment of $200,000 in Shenzhen CQENS. This investment will be used to fund operations in Shenzhen.

We are dependent upon joint ventures and third-party marketing and distribution companies, including Firebird Manufacturing, LLC ("Firebird") for the manufacturing of our future products. We believe that our business opportunities are global and may include partnerships in the USA, UK, the EU and Asia, including the People's Republic of China. We may face challenges entering into further strategic partnerships.

The COVID-19 pandemic, global conflicts, government shutdowns, and inflationary conditions have caused certain delays in the development of our HTP products. Our product development and commercialization timelines have been reset but are moving forward and we expect to adhere to our schedule over the next 12 months. Key milestones for us over these next 12 months include completion of the Premarket Tobacco Product Application (PMTA) process, securing a strategic partner, raising capital for commercialization of products, finalizing the joint venture with Firebird for manufacturing of our consumable and distribution of our devices and consumables in the United States. Any prolonged inflationary pressures on the capital markets will make it more difficult for small, pre-revenue companies such as our company to raise capital. We continue to assess the impact of any inflationary conditions on our company, and at this time, we are unable to predict all possible impacts on our company, our operations and our prospects.

Basis of Presentation

*Basis of Presentation* - The following unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, such interim consolidated financial statements do not include all the information and footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete annual consolidated financial statements. The information furnished reflects all adjustments, consisting only of normal recurring items which are, in the opinion of management, necessary to make the consolidated financial statements not misleading. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. The balance sheet as of March 31, 2026, has been derived from the Company's annual consolidated financial statements that were audited by our independent registered public accounting firm but does not include all of the information and footnotes required for complete annual consolidated financial statements. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2025, and filed with the SEC on April 15, 2026, for a broader discussion of our business and the risks inherent in such business.

The consolidated financial statements include the accounts of the Company and its subsidiaries in which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation. The Company consolidates variable interest entities for which it is the primary beneficiary in accordance with ASC 810.

*Segment Information -* In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which introduced new guidance for improving disclosures about a public entity's reporting segments to provide, when applicable, more detailed information about a reportable segment's expenses. This standard was effective for the Company as of January 1, 2024. The senior management team consisting of the CEO, CFO and COO collectively are identified as the Chief Operating Decision Maker (CODM). The CODM, for the Company, has determined, consistent with the guidance in ASC 280 paragraph 280-10-50-1, that CQENS Technologies, its subsidiary, CQENS Electronics (Hong Kong) Limited ("CEL") and Shenzhen CQENS are a single operating and reporting segment. The CODM has chosen to organize the Company around differences in products and services. CQENS, CEL and Shenzhen CQENS are focused on research and development of our HnB technology and on production and commercialization of this same technology. The CODM evaluates the Company's financial information and resources and assesses the performance of these resources on a consolidated and aggregate basis. Accordingly, the Company has determined that it operates in one operating and reportable segment. The Company internally reports the following segment financial information, on a consolidated basis, to the CODM: research and development expenses and professional fees, are the key contributors used to measure the reported losses used by the CODM to assess performance and allocate resources and is presented on the consolidated statements of operations and comprehensive loss. There are no segment operating expenses that require disclosure beyond the expense categories presented on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the consolidated balance sheets as total assets. As a result, there are no additional disclosures required and no impact to our financial statements at adoption.

*Variable Interest Entity ("VIE") -* The Financial Accounting Standards Board ("FASB") provides guidance in ASC 810, Consolidation ("ASC 810") for determining whether an entity is a VIE. VIE's are defined as entities in which equity investors of the entity do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support. A VIE is required to be consolidated by its primary beneficiary, which is the party that (i) has the power to control the activities that most significantly impact the VIE's economic performance and (ii) has the obligation to absorb losses, or the right to receive benefits, of the VIE that could potentially be significant to the VIE. The Company enters business relationships and regularly assesses them under the requirements of ASC 810 to determine whether such relationships should be accounted for under the VIE model and if so, whether the Company is the primary beneficiary of the VIE.

The Company concluded it has a variable interest in CEL that results in the Company being the primary beneficiary. This conclusion was based on the following:

● The Company inherently has the power to direct the activities of CEL as its sole customer.

● Without the business of the Company, CEL would not be able to sustain their operations.

The following table summarizes the carrying amount of the assets and liabilities of CEL included in the Company's Consolidated Balance Sheets as of March 31, 2026.

---

| | |
|:---|:---|
|  | March 31, 2026 |
| Cash and cash equivalents | $1237611 |
| Prepaid Expenses | $150631 |
| Total Assets | $1388242 |
| Related party loan | $276411 |
| Customer deposit | $172972 |
| Total Liabilities | $449383 |

---

The results of operations of CEL are included in the Company's consolidated financial statements.

*Recent Accounting Pronouncements* – On November 4, 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03 which issues new guidance requiring disclosure of the disaggregation of income statement expenses (DISE) by public business entities (PBE's) and is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting the standard. The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying consolidated financial statements.

**NOTE 2 – GOING CONCERN** 

The Company's consolidated financial statements are prepared in accordance with GAAP applicable to a going concern. This contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company has recurring losses, with continued research and development efforts, no source of revenue and limited cash sufficient to cover its operations. Management believes we have sufficient capital to complete the PMTA process that will encompass at least the next 12 months from the issuance of these consolidated financial statements, barring any unforeseen event or circumstance. In the event of any unforeseen costs to complete the PMTA process, we will be unable to meet our current obligations. These factors may not allow us to continue as a going concern. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company will be dependent upon the raising of additional capital. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

**NOTE 3 – STOCKHOLDERS' EQUITY** 

In the first quarter of 2026, we sold 6,000 shares of our common stock for $120,000 in private transactions. We did not pay commissions or finder's fees and are using proceeds for working capital.

In the first quarter of 2025, we sold 503,750 shares of our common stock for $10,075,000 in private transactions. We did not pay commissions or finder's fees and are using the proceeds for working capital.

In the first quarter of 2025, we issued 45,169 shares of our common stock to unrelated third parties as compensation for their consulting services. The stock was valued at $903,380.

As of March 31, 2026, the Company had 27,579,752 shares of common stock issued and outstanding.

The following table represents option activity for the three months ended March 31, 2026:

SCHEDULE OF OPTION ACTIVITY

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Number of<br> Options | Weighted<br> Average<br> Exercise<br> Price | Weighted<br> Average<br> Remaining<br> Contractual <br> Life<br> in Years | Aggregate<br> Intrinsic Value |
| Outstanding – December 31, 2025 | 2011024 | $12.45 | 3.34 | $15178592 |
| Exercisable – December 31, 2025 | 1679224 | $12.38 | 2.92 | $12788592 |
| Granted | - | $- |  |  |
| Forfeited | 200000 | $- |  |  |
| Vested | - |  |  |  |
| Outstanding – March 31, 2026 | 1811024 | $13.05 | 3.45 | $12578592 |
| Exercisable - March 31, 2026 | 1479224 | $13.11 | 3.05 | $10188592 |

---

During the first quarter of 2026 we recorded $199,851 in stock option expenses compared to $460,019 in the first quarter of 2025.

**NOTE 4 – RELATED PARTY TRANSACTIONS** 

Prior to 2026 we borrowed $900,000 from Xten Capital Group, a common control entity and affiliate of Alexander Chong, the Company's principal shareholder and Chief Executive Officer. In the first quarters of 2026 and 2025 there were no transactions with Xten. The balance of the loan on March 31, 2026, is $900,000. The loan is unsecured, non-interest bearing and due upon demand.

In the first quarter of 2026, CQENS Electronics (Hong Kong) Limited ("CEL"), a subsidiary of CQENS, did not borrow funds from Ann Liu, CEL's managing director, while in the first quarter of 2025, CEL borrowed $60,612. The loan is for operations and is unsecured, non-interest bearing and due on demand. The loan balance due to Ann Liu at March 31, 2026 is $79,239. In the first quarter of 2026 we borrowed $139,870 from Asahi Corporation Limited a common control entity of Ann Liu, and our joint venture partner of CEL. There was no borrowing in the first quarter of 2025. The balance due to Asahi at March 31, 2026 is $197,172. The loan is unsecured, non-interest bearing and due on demand.

In October 2025 we established operations in Shenzhen, China, organizing Shenzhen CQENS Technology Company Limited ("Shenzhen CQENS") and in doing so we borrowed money from two individuals related to this start-up. In the first quarter of 2026 we borrowed $90,172 from Tianyang Zhang and $21 from Xinjie Liu to fund operations. The balance owed to Mr. Zhang at March 31, 2026 is $302,295. The balance owed to Mr. Liu at March 31, 2026 is $7,721. The loans are unsecured, non-interest bearing and due on demand. Mr. Zhang is a consultant for CQENS. Mr. Liu is the office manager of Shenzhen CQENS.

We engaged Plexus International (Plexus), a common control entity Alexander Chong, our CEO, due to their expertise in providing consulting services to assist in creating and implementing our Quality Management System (QMS). In the first quarter of 2026 the fees were $9,000 while the fees and expenses in the first quarter of 2025 were $44,225. Plexus provides accounting and project management services to us as needed. In the first quarter of 2026 the fees were $15,000 for project management and $463 for accounting services. In the first quarter of 2025, Plexus provided only accounting services and the fees were $463.

**NOTE 5 – LEASES**

In March 2022 we entered into a three-year lease agreement commencing April 15, 2022 and continuing through April 30, 2025, for our research and development office located in Aptos, CA. In April 2025 we extended the lease for two additional years commencing May 1, 2025 and continuing through April 30, 2027. The annual rate for the initial term of the lease extension is $70,785 with installment payments of $5,555 in May 2025 and $5,930 each month thereafter. Annual increases are tied to the U.S. Consumer Price Index of the Bureau of Labor Statistics of the Department of Labor for all Urban Consumers for San Francisco-Oakland-San Jose area. Beginning May 1, 2026, the fixed common area costs which are part of the lease increased and the monthly payment of $5,930 will increase to $6,020 per month for the balance of the lease that extends through April 30, 2027.

In October 2025, we entered into a two-year lease agreement in Shenzhen, China, commencing November 10, 2025, and continuing through November 9, 2027. The lease rate remains constant for the term of the lease. The annual rate is $58,536 with installment payments of $4,878 each month.

We account for our leases under ASC 842, Leases, which requires all leases to be reported on the balance sheet as right-of-use assets and lease obligations. We elected the expedients permitted under the transition guidance that retained lease classification and initial direct costs for any leases that existed prior to adoption of the standard.

We categorized leases with terms longer than twelve months as either operating or finance. Finance leases are generally those leases that would allow us to substantially utilize or pay for the entire asset over its estimated life. Assets acquired under finance leases are recorded in property and equipment, net. All other leases are categorized as operating leases. We did not have any finance leases as of March 31, 2026. Our lease for the property is for three years. We elected the accounting policy to include both the lease and non-lease components of our agreements as a single component and account for them as a lease.

Lease liabilities are recognized at the present value of the fixed lease payments using a discount rate based on similarly secured borrowings available to us. Lease assets are recognized based on the initial present value of the fixed lease payments, reduced by landlord incentives, plus any direct costs from executing the lease. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Leasehold improvements are capitalized at cost over the lesser of their expected useful life or the lease term.

When we have options to extend the lease term, terminate the lease before the contractual expiration date, or purchase the leased asset, and it is reasonably certain that we will exercise the option, we consider these options in determining the classification and measurement of the lease. Costs associated with the operating lease are recognized on a straight-line basis within operating expenses over the term of the lease.

**NOTE 6 – CONSTRUCTION IN PROGRESS** 

On July 13, 2022 the Company entered into a manufacturing contract with Montrade S.p.A., ("Montrade"), an industry leading designer and manufacturer of machines for a wide range of products, including heated tobacco products (HTP), based in Bologna, Italy, for the manufacture and installation of our proprietary HTP consumables manufacturing equipment. The Company made an initial payment of $589,265. Throughout the construction we made 6 amendments to the initial contract. The equipment is completed and is in final assembly testing. On March 31, 2026, the balance owing for the construction, installation, travel and training is $372,164.

On June 3, 2025, CQENS entered into an agreement with Montrade for the development, manufacture, delivery and installation of a higher volume machine to manufacture consumables for the Company's proprietary, patented and patent pending HnB system. We made an initial down payment of $1,016,531 on June 4, 2025. The design phase was completed in November 2025, and we paid the balance for this phase in December 2025 expensing a total of $302,299 for the design phase. On March 31, 2026, the balance remaining under the agreement is $1,839,348.

**NOTE 7 – SUBSEQUENT EVENTS** 

On May 1, 2026, we sold 2,500 shares of our common stock for $50,000 in a private transaction. We did not pay a commission or finder's fee and are using proceeds for working capital.

On May 12, 2026, we sold 500 shares of our common stock for $10,000 in a private transaction. We did not pay a commission or finder's fee and are using the proceeds for working capital.

On May 1, 2026, we made a $200,000 investment in Shenzhen CQENS. The funds will be used to fund operations.

On April 21, 2026, we paid Montrade $88,500 for work completed under the 2022 manufacturing contract as amended. Following this payment the balance owing under the 2022 agreement is $291,470.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

The following discussion of our financial condition and results of operations for the three months ended March 31, 2026 and 2025 should be read in conjunction with the unaudited consolidated financial statements and the notes to those statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under "Cautionary Statements Regarding Forward-Looking Information" appearing earlier in this report, Part I. Item 1A. Risk Factors appearing in our 2025 10-K, and our other filings with the Securities and Exchange Commission. We use words such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could," and similar expressions to identify forward looking statements. In addition, any statements that refer to projections of our future financial performance, our anticipated growth and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements. Such statements are based on our current expectations and could be affected by the uncertainties and risk factors described throughout this report.

**Overview** 

We are a technology company. We design and develop innovative methods to heat plant-based and/or medicant-infused formulations to produce aerosols for the efficient and efficacious inhalation of the plant and medicant constituents contained therein. We have two ways of accomplishing this: 1) at high temperatures via induction without combustion or the constituents of combustion; and 2) at low temperatures, where we heat an inert carrier, producing inhalable, medicant-infused aerosols while maintaining the integrity of the active ingredient(s).

Our high-temperature non-combusting technology is supported by 86 U.S. and international patents and pending patents. Among the applications of our patented and patent-pending technology are those for Heat-not-Burn ("HnB") devices. Independent tests performed by an accredited lab on our system's prototypes supported the benefits of rapid heating, confirmed non-combustion, even at high temperatures, and produced better toxicology results, greater than 99% better, when compared to products requiring combustion. And when compared to other non-combusting technologies currently on the market, our results were superior.

Our low-temperature, aerosolizing technology is supported by 30 U.S. and international patents and pending patents. This portfolio includes intellectual property around device designs and formulations containing a wide variety of herbal and pharmaceutical preparations. The development stage devices feature the ability to verify the user, validate the medicant or pharmaceutical preparation and measure, meter and monitor the proper, prescribed dosage.

Today we define one of our target markets as the world-wide combustible tobacco market. Grand View Research, a global leader in market reports and industry statistics, estimates that the global tobacco market size was USD 926.0 billion in 2025, and is projected to reach USD 1,144.2 billion in 2033, growing at a CAGR of 2.7% from 2026 to 2033. Our near-term focus is on the heated, non-combusting modified risk tobacco segment which we believe represents our greatest opportunity for growth and the greatest opportunity to positively impact public health and wellness.

On August 17, 2021, we entered into a Joint Venture Agreement (the "JV Agreement") with Firebird Manufacturing, LLC ("Firebird"), a Barker Group company. Under the terms of the JV Agreement the parties have agreed to organize, negotiate, and establish a limited liability company joint venture entity (the "Joint Venture Entity") for the purposes of developing, manufacturing, and distributing HnB products in the United States. The Joint Venture Entity will be owned equally by Firebird and the Company. Firebird will be responsible for manufacturing the consumable and distributing both the device and consumables to the retail locations where the product can be lawfully sold in the United States.

Formation of the Joint Venture Entity is subject to formalizing and executing the Joint Venture Operating Agreement and additional agreements, including a license agreement for the use of intellectual property, certain product development agreements, supply agreements and such other agreements as may be necessary to further the purpose of the JV Agreement. The parties anticipate completing the relevant agreements in 2026 although there are no assurances that the parties will complete and formalize these agreements.

On July 13, 2022 the Company entered into a manufacturing contract with Montrade S.p.A., ("Montrade"), an industry leading designer and manufacturer of machines for a wide range of products, including heated tobacco products (HTP), based in Bologna, Italy, for the manufacture and installation of our proprietary HTP consumables manufacturing equipment. The Company made an initial payment of $589,265. The equipment is completed and is in final assembly testing. On March 31, 2026, the balance owing for the construction, installation, travel and training is $372,164.

On June 3, 2025, CQENS entered into an additional agreement with Montrade for the development, manufacture, delivery and installation of a higher volume machine to manufacture consumables for the Company's proprietary, patented and patent pending HnB system. We made an initial down payment of $1,016,531 on June 4th, 2025. The design phase was completed in November 2025 and we paid the balance for this phase in December 2025 expensing a total of $302,299 for the design phase. On March 31, 2026, the balance remaining under this Agreement is $1,839,348.

On December 20, 2023 we entered into a Shareholder Agreement with Asahi Corporation to establish CQENS Electronics (Hong Kong) Limited ("CEL"), a Hong Kong company, for design, development and manufacture of our heat-not-burn device. CQENS acquired 50% membership of CEL and holds majority of the board seats including the chair. Pursuant to the establishment of CEL, CQENS entered into an exclusive, worldwide license agreement with CEL for designing, manufacturing a consumer device consistent with our IP.

In October 2025, we set-up a research and development operation in Shenzhen, China to support our US-based research and development efforts and to take our prototype device through the design for manufacturability for mass manufacturing. In November, 2025, we secured a facility and entered into a two-year lease agreement with fixed rent for the term of the lease. The monthly rent is approximately $4,878 USD per month. In January 2026, we formed Shenzhen CQENS, a wholly owned foreign entity in China, for these research and development activities in Shenzhen China.

As the largest category within the global inhalation market is the combustible tobacco market, comprising over 90% of the total inhalation market, our near-term focus is on this segment, which represents the greatest opportunity for growth and the greatest opportunity to positively impact public health and wellness. To this end we have added three critical senior executives to our management team with decades of experience in the tobacco and next-generation sectors filling our Chief Operating Officer, Chief Commercial Officer and Chief Technical Officer roles. Their experience is extensive and includes executing global commercial strategy; development and scaling of reduced-risk product portfolios across multiple international markets; machinery and manufacturing solutions in the tobacco and next generations product sectors.

Further, we have assembled a team of engineers in Shenzhen, China to work closely with our US-based research and development engineering team and our Hong Kong based joint venture entity, CQENS Electronics (Hong Kong) Limited, to complete the design for manufacturability of our launch products. And with our Hong Kong JV are working to secure national and international certification markings.

Our joint venture partner in Hong Kong has sourced and secured suppliers for the device components, completed the tooling and is focused on the production process for mass manufacturing of our devices.

US-based Firebird, is in the midst of construction of a new and much larger facility where the consumable manufacturing production line equipment will be installed for the mass production of our consumables.

We have retained the services of a related party, Plexus Corporation, to consult with us in the design and development of our quality management systems within our corporate office and throughout our joint ventures and reaching to our suppliers and will work to ensure the manufacturing facilities are GMP compliant.

We have retained Jefferies, a leading investment banker and capital markets firm, to explore the opportunities to secure a long-term strategic partnership or to secure the capital resources necessary to successfully commercialize our products. We have also retained Munger, Tolles and Olsen LLP who will assist in the negotiation process. We have not identified any opportunities as of the date of this report.

We have retained McKinney Regulatory Science Advisors LLC and Applied Research & Analysis Company LLC (ARAC) to consult, conduct trials and testing, and assist us as we navigate through the PMTA process.

We have met with the FDA and we believe we have received clear guidance on a path forward for conducting clinical trials.

**Going concern** 

For the first three months of 2026, we reported a consolidated net loss of $1,376,821 and net cash used in operations of $979,322 compared to a net loss of $2,493,777 and net cash used in operations of $1,117,372 for the first three months of 2025. At March 31, 2026, we had cash on hand of $8,194,093 and an accumulated deficit of $49,163,580. The report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2025, contains an explanatory paragraph regarding our ability to continue as a going concern based upon our recurring losses and no source of revenues which are sufficient to cover our operating costs. These factors, among others, raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Results of operations** 

We did not generate any revenues from our operations in the first three months of 2026 or 2025.

Our total operating expenses for the three months ended March 31, 2026 decreased 44.6% over those reported for the same period in 2025. This decrease is primarily attributable to a decrease in professional fees. The decrease was partially offset by an increase in general and administrative expenses of 32.3% and increases in amortization, rent and travel related costs. An increase in research and development expenses of 41.4% due to increased engineering services also offset some of this decrease in the first three months of 2026 versus this same period in 2025.

We expect that our operating expenses will increase as we continue to develop and grow our business and we devote additional resources toward research and development and business opportunities, promoting that growth, most notably reflected in anticipated increases in general overhead, salaries for personnel and technical resources, as well as increased costs associated with the PMTA process and legal and professional fees. However, while we believe we have adequate working capital to complete the PMTA process over the next 12 months, as set forth elsewhere in this report, our ability to continue to develop our business and achieve our operational goals is dependent upon our ability to raise significant additional working capital. As the availability of this capital is unknown, we are unable to quantify at this time the expected increases in operating expenses in future periods.

**Liquidity and capital resources** 

As of March 31, 2026, we had $8,149,093 in cash and cash equivalents and a working capital surplus of $6,280,456 compared to $8,914,107 in cash and cash equivalents and a working capital surplus of $7,427,664 at December 31, 2025. Our current liabilities increased $338,062 from December 31, 2025, reflecting a slight increase in our accounts payable, accrued expenses, and related party borrowing. Our source of operating capital in the first three months of 2026 came from cash on hand at the end of 2025 of $8,914,107, the sale of 6,000 shares of common stock for gross proceeds of $120,000, borrowing from related parties of $230,063 and earned interest of $51,049. Our source of operating capital in the first quarter of 2025 came from the sale of 503,750 shares of common stock for gross proceeds of $10,075,000 which includes $850,000 of investor deposits, borrowing from a related party of $60,612, and earned interest of $88,827.

The ability of the Company to continue as a going concern is dependent upon the Company obtaining adequate capital to fund operating losses until it becomes profitable. As the company is not generating revenues, continued activities and expenditures to bring product(s) to market as soon as we are able is important.

In the first three months of 2025, CEL borrowed $60,612 from Ann Liu, a related party. In the first quarter of 2026 we borrowed $139,870 from Asahi, our joint venture partner in Hong Kong. There was no borrowing from Asahi in the first quarter of 2025. In the first quarter of 2026 we borrowed $90,172 from Tianyang Zhang a related party in our Shenzhen operations, for working capital. We did not borrow from Mr. Zhang in the first quarter of 2025. As of March 31, 2026, we owe: Xten $900,000; Ann Liu $79,239; Asahi $197,172; Tianyang Zhang $302,295, and; $7,721 to Xinjie Liu. The loans are unsecured, non-interest bearing and due on demand. As of March 31, 2026 and as of the date of this filing, we owe an aggregate of $1,486,427 to related parties.

As of the date of the filing of this report we believe we have sufficient capital to fund the next 12 months, however there is no assurance we will have sufficient funds for commercialization of any products. There is no assurance we will have sufficient funds due to circumstances beyond our control including regulatory changes, delays or additional regulatory requirements.

In January 2026, we established our wholly owned subsidiary in China, Shenzhen CQENS. We made an initial capital investment of $200,000 and a subsequent investment of an additional $200,000. This subsidiary will be primarily used for research and development working in concert with our US-based team and with CQENS Electronics (Hong Kong) Limited to move prototypes through the design for manufacturability process.

Summary of cash flows

---

| | | |
|:---|:---|:---|
|  | March 31, 2026 | March 31, 2025 |
| Net cash (used) in operating activities | $(979322) | $(1117372) |
| Net cash (used) in investing activities | $(125962) | $(1017092) |
| Net cash provided by financing activities | $350063 | $9385612 |

---

Our cash used in operating activities decreased 12.4% in the first three months of 2026 compared to the first three months of 2025. During these time periods, we primarily used the cash to fund our net losses.

In the first three months of 2026, there was $125,962 net cash used in investing activities from the capitalization of our intellectual property and addition to intangible assets compared to net cash used in investing activities of $1,017,092 in the same period in 2025 for capitalization of our intellectual property and additions to property plant and equipment.

In the first three months of 2026, we had net cash provided by financing activities of $350,063 from the sale of our common stock and borrowing from related parties. We had net cash provided by financing activities in the first three months of 2025 of $9,385,612 from the sale of our common stock, investor deposits and borrowing from related parties.

**Critical accounting policies** 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. We also have other key accounting policies, none of these policies are deemed to be critical accounting policies or critical estimates.

**Recent Accounting Pronouncements**

On November 4, 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03 which issues new guidance requiring disclosure of the disaggregation of income statement expenses (DISE) by public business entities (PBE's) and is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting the standard. The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying consolidated financial statements.

**Off balance sheet arrangements** 

As of the date of this report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.** 

Not applicable for a smaller reporting company.

**Item 4. Controls and Procedures.** 

Evaluation of Disclosure Controls and Procedures.

We maintain "disclosure controls and procedures" as such term is defined in Rules 13a-15(e) under the Securities Exchange Act of 1934. In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on their evaluation as of the end of the period covered by this report, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were not effective to ensure that the information relating to our company required to be disclosed in our SEC reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer, to allow timely decisions regarding required disclosure due to the presence of continuing material weakness in our internal control over financial reporting as reported in our 2025 10-K. These material weaknesses in our internal control over financial reporting result from limited segregation of duties and limited multiple level of review in the financial close process.

The existence of the continuing material weaknesses in our internal control over financial reporting increases the risk that a future restatement of our financials is possible. In order to remediate these material weaknesses, we will need to expand our accounting resources. We will continue to monitor and evaluate the effectiveness of our disclosure controls and procedures and our internal control over financial reporting on an ongoing basis, however, we do not expect that the deficiencies in our disclosure controls will be remediated until such time as we have remediated the material weaknesses in our internal control over financial reporting. Subject to the availability of sufficient capital, we expect to expand our accounting resources in the latter half of 2026 in an effort to remediate the material weaknesses in our internal control over financial reporting.

Changes in Internal Control over Financial Reporting.

There have been no changes in our internal control over financial reporting during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings.**

None.

**Item 1A. Risk Factors.**

In addition to the other information set forth in this report you should carefully consider the risk factors in Part I, Item 1A in our 2025 10-K, which could materially affect our business, financial condition or future results. These cautionary statements are to be used as a reference in connection with any forward-looking statements, written or oral, which may be made or otherwise addressed in connection with a forward-looking statement or contained in any of our subsequent filings with the Securities and Exchange Commission.

*We may be unsuccessful in our efforts to commercialize and grow HnB products in existing and new markets, and government regulation may prohibit or significantly restrict the commercialization of these products or the communication of scientifically substantiated information and claims.*

Our priority is the development, commercialization and growth of our HnB technology and if these efforts are not successful, in key markets or systematically, our financial results and future growth prospects may be materially adversely impacted. If other market participants are more successful in these efforts or if HnB categories are inequitably regulated compared to cigarettes or other HnB categories without regard to the totality of the scientific evidence available for such products, we may be at a competitive disadvantage. In addition, actions of some market participants, such as the inappropriate marketing of e-vapor products to youth, as well as alleged health consequences associated with the use of certain HnB products, may unfavorably impact public opinion and/or mischaracterize the health consequences of our HnB products to consumers, regulators and policy makers without regard to the totality of scientific evidence available for specific products. This may impede our efforts to advocate for the development and maintenance of science-based regulatory frameworks for the development and commercialization of HnB technology. We cannot predict the extent to which regulators will permit - or continue to permit - the sale and/or marketing of HnB products and regulatory restrictions have, and could further limit, the development and commercialization of our HnB technology.

Additionally, any claims, regardless of merit, challenging our research and clinical data available to date, may impact the development and maintenance of science-based regulatory frameworks for the commercialization of the HnB category and the commercialization of the HnB category in general.

Our HnB technology will be designed for, and directed toward, current adult smokers and adult users of nicotine-containing products. We intend to make significant efforts to restrict access of our products from underage persons. Despite our efforts, technological, operational, regulatory and/or commercial developments might impact the implementation or effectiveness of youth access prevention mechanisms and surrounding infrastructure. If there is significant usage, whether actual or perceived, of our products or competitive products among youth or non-nicotine users, even in situations over which we have no control, our reputation and credibility may suffer, the regulatory approach to our products may become more restrictive, and our efforts to advocate for the development of science-based regulatory frameworks for the development and commercialization of HnB technology may be significantly impacted.

**The financial and business performance of our HnB products may be unpredictable.**

Upon development and introduction, our HnB devices will compete in relatively new categories, and the pace at which adult smokers adopt them may vary, depending on the competitive, regulatory, fiscal and cultural environment, and other factors in a specific market. There may be periods of accelerated growth and periods of slower growth for these products, the timing and drivers of which may be difficult for us to predict. The impact of this lower predictability on our projected results for a specific period may be significant, due to geopolitical or macroeconomic events that negatively impact HnB availability or adoption, which in turn may have a material adverse effect on our results of operations.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

During the period covered by this report the Company issued the unregistered shares of common stock, as noted below, pursuant to exemptions from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended. The shares contain restrictions on the transferability of such shares, absent registration or applicable exemption.

During the first quarter of 2026, we sold an aggregate of 6,000 shares of our common stock for $120,000 in private transactions to two accredited investors. We did not pay a commission of finder's fee and are using the proceeds for working capital.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable to our company's operations.

**Item 5. Other Information.**

The Auditor Firm ID for our external auditors, MaloneBailey, LLP, is 206.

During the quarterly period ended March 31, 2026, no officers (as defined in Rule 16a-1(f)) or directors adopted or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K).

**Item 6. Exhibits.** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **No.** | **Exhibit Description** | **Form** | **Date Filed** | **Number** | **Herewith** |
| 2.1 | [Share Exchange Agreement and Plan of Reorganization dated April 11, 2014 by and between OICco Acquisition IV, Inc., VapAria Corporation and the listed shareholders+](https://www.sec.gov/Archives/edgar/data/1479915/000107878214000620/f8k041014_ex2za.htm) | 8-K | 4/11/14 | 2a |  |
| 3.1 | [Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1479915/000138713114002338/ex-3c.htm) | POSAM | 6/30/14 | 3.C |  |
| 3.2 | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1479915/000138713114003078/ex3-4.htm) | 8-K | 8/21/14 | 3.4 |  |
| 3.3 | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1479915/000149315216014674/ex3-5.htm) | 10-Q | 11/09/16 | 3.5 |  |
| 3.4 | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1479915/000149315219019391/ex3-5.htm) | 8-K | 12/18/19 | 3.5 |  |
| 3.5 | [Bylaws](https://www.sec.gov/Archives/edgar/data/1479915/000107878210000567/oicco4s1ex3b.htm) | S-1 | 3/29/10 | 3(b) |  |
| 31.1 | [Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer](ex31-1.htm) |  |  |  | Filed |
| 31.2 | [Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer and Chief Financial Officer](ex31-2.htm) |  |  |  | Filed |
| 32.1 | [Section 1350 Certification](ex32-1.htm) |  |  |  | Furnished\* |
| 101.INS | Inline XBRL Instance Document |  |  |  | Filed |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  | Filed |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  | Filed |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  | Filed |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  | Filed |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  | Filed |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |  |  |  |  |

---

+ Exhibits and/or Schedules have been omitted. The Company hereby agrees to furnish to the Staff of the Securities and Exchange Commission upon request any omitted information.

\* This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | CQENS Technologies Inc. | CQENS Technologies Inc. |
| May 14, 2026 | By: | */s/ Alexander Chong* |
|  |  | Alexander Chong, Chief Executive Officer |
| May 14, 2026 | By: | */s/ Daniel Markes* |
|  |  | Daniel Markes, Chief Financial Officer |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**Rule 13a-14(a)/15d-14(a) Certification**

I, Alexander Chong, certify that:

1. I
 have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2026 of CQENS Technologies Inc.

2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
 to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
 the period covered by this report;

3. Based
 on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in
 all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
 presented in this report;

4. The
 registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
 within those entities, particularly during the period in which this report is being prepared;

(b) Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated
 financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
 the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
 and

(d) Disclosed
 in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
 most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
 or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The
 registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
 financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or
 persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
 and

(b) Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
 internal control over financial reporting.

---

| | |
|:---|:---|
| May 14, 2026 | */s/ Alexander Chong* |
|  | Alexander Chong, Chief Executive Officer,<br> principal executive officer |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**Rule 13a-14(a)/15d-14(a) Certification**

I, Daniel Markes, certify that:

1. I
 have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2026 of CQENS Technologies Inc.

2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
 to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
 the period covered by this report;

3. Based
 on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in
 all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
 presented in this report;

4. The
 registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
 within those entities, particularly during the period in which this report is being prepared;

(b) Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated
 financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
 the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
 and

(d) Disclosed
 in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
 most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
 or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The
 registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
 financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or
 persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
 and

(b) Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
 internal control over financial reporting.

---

| | |
|:---|:---|
| May 14, 2026 | */s/ Daniel Markes* |
|  | Daniel Markes, Chief Financial Officer,<br> principal financial and accounting officer |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**Section 1350 Certification**

In connection with the Quarterly Report of CQENS Technologies Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026 as filed with the Securities and Exchange Commission (the "Report"), I, Alexander Chong, Chief Executive Officer of the Company, and I, Daniel Markes, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;1. The
 Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

2. The
 information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations
 of the Company.

---

| | |
|:---|:---|
| May 14, 2026 | */s/ Alexander Chong* |
|  | Alexander Chong, Chief Executive Officer,<br> principal executive officer |
| May 14, 2026 | */s/ Daniel Markes* |
|  | Daniel Markes, Chief Financial Officer,<br> principal financial and accounting officer |

---

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.